Wei‐Wen Su

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

Tung‐Hung Su, Tsung‐Hui Hu, Chi‐Yi Chen et al. · Liver International · 2016 · 217 citations

Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses

Chun‐Jen Liu, Wan‐Long Chuang, Chuan–Mo Lee et al. · Gastroenterology · 2008 · 212 citations · Full text

Dual Chronic Infection, Hepatology, Hepatitis C +11

Disturbance of circadian gene expression in hepatocellular carcinoma

Yueh‐Min Lin, Julia Huei‐Mei Chang, Kun‐Tu Yeh et al. · Molecular Carcinogenesis · 2008 · 165 citations